Krka Enjoys ‘Strongest’ Half Year, Although Prescription Stagnates
Slovenian Firm Publishes Preliminary Results
Executive Summary
Having picked up five prescription marketing authorization approvals in the first half of 2021, Slovenian generics giant Krka will be hoping to build on stagnant prescription pharmaceuticals reported in preliminary financial results.
You may also be interested in...
Krka’s Zytiga Rival Wins CHMP Nod
Krka’s generic version of Janssen’s Zytiga has garnered a positive opinion from the EMA’s CHMP, along with Pinax Pharma’s Celsunax ioflupane generic of DaTSCAN and Nova Laboratories’ hybrid Jayempi azathioprine oral suspension.
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
Cigna: US Adalimumab Prices Could Vary Meaningfully
Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.